0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Siglec-2

Siglec-2

Siglec-2 Molecule Information

Name:CD22
Target Synonym:B-Lymphocyte Cell Adhesion Molecule,SIGLEC2,BL-CAM,Siglec-2,Sialic Acid Binding Ig-like Lectin 2,B-cell receptor CD22,Sialic acid-binding Ig-like lectin 2,T-cell surface antigen Leu-14,CD22,CD22 Molecule,CD22 Antigen
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:32
Lastest Research Phase:Approved

Siglec-2 Protein Product ListCompare or Buy

Siglec-2 Part of Bioactivity data

SI2-HF2H6-Cell-based assay
Evaluation of CAR expression

293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6, 10 µg/mL) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6) (QC tested).

SI2-H5228-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-Human CD22 MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human Siglec-2 (176-687), His Tag (Cat. No. SI2-H5228) with an affinity constant of 11.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD2-H52H8-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Anti-Human CD22 MAb (human IgG1) on AHC Biosensor, can bind Human Siglec-2, His Tag (Cat. No. CD2-H52H8) with an affinity constant of 133 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Siglec-2 Molecule Synonym Name

CD22,SIGLEC2,BL-CAM,SIGLEC-2,Siglec2,SIGLEC2FLJ22814

Siglec-2 Molecule Background

B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Siglec-2 References

Siglec-2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Inotuzumab Ozogamicin CMC-544; WAY-207294; PF-5208773 Approved Pfizer Inc, Ucb Besponsa Japan Precursor Cell Lymphoblastic Leukemia-Lymphoma s:10:"Pfizer Inc"; 2017-06-28 Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma Details
Moxetumomab pasudotox HA-22; CAT-8015; GCR-8015 Approved Astrazeneca Plc Lumoxiti EU Leukemia, Hairy Cell s:14:"Astrazeneca Ab"; 2018-09-13 Leukemia, Hairy Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic Details

Siglec-2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti CD22 chimeric antigen receptor T cell therapy (Shanghai Yake Biotechnology) Phase 2 Clinical Yake Biotechnology, Beijing Boren Hospital, The First Affiliated Hospital Of Zhejiang University School Of Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
BAY-1862864 BAY-1862864 Phase 1 Clinical Bayer Ag Lymphoma, Non-Hodgkin Details
Epratuzumab AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2 Phase 3 Clinical Immunomedics Inc Lymphoma, B-Cell; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) Phase 1 Clinical Hebei Senlang Biological Technology Co Ltd Sarcoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) Phase 1 Clinical Persongen Biotherapeutics Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms, Plasma Cell Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Leukemia; Lymphoma Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase 1 Clinical Ut Southwestern Medical Center Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
UCART-22 UCART-22 Phase 1 Clinical Cellectis Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) Phase 2 Clinical The University Of Texas M.D. Anderson Cancer Center Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase 1 Clinical Seattle Children'S Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) Phase 1 Clinical Hrain Biotechnology Leukemia, Lymphoid Details
GTB-1550 DT-2219; OXS-1550; DT-2219ARL; IND-100780 Phase 2 Clinical University Of Minnesota Leukemia; Lymphoma, B-Cell Details
Anti-CD22 CAR-T cell therapy (iCarTAB BioMed) Phase 2 Clinical Icar Bio, China Lymphoma, B-Cell Details
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) Phase 1 Clinical Shanghai Genechem Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD22-CART Phase 1 Clinical Hrain Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell Details
TRPH-222 CD22-4AP; TRPH-222; CAT-02-106 Phase 1 Clinical Catalent Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin Details
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) Phase 1 Clinical The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) Phase 1 Clinical Wuhan Bio-Raid Biotechnology Lymphoma, B-Cell; Multiple Myeloma Details
AUTO-3 AUTO-3 Phase 2 Clinical University College London Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Leukemia; Lymphoma, B-Cell Details
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) Phase 2 Clinical Kecellitics Biotech Company Ltd Leukemia; Lymphoma Details
RD-102 RD-102 Phase 1 Clinical Nanjing Iaso Biotherapeutics Co Ltd Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase 1 Clinical Stanford University Lymphoma, B-Cell Details
JCAR-018 JCAR-018 Phase 1 Clinical National Cancer Institute, Opus Bio Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Hematologic Neoplasms Details
CART22-cells CART22-cells Phase 1 Clinical Novartis Pharma Ag, University Of Pennsylvania Leukemia; Lymphoma, B-Cell Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase 1 Clinical Shanghai Jiaotong University Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) LCAR-L10D Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University Lymphoma, Large B-Cell, Diffuse Details
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) Phase 2 Clinical The Fifth Medical Center Of Chinese Pla General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) Phase 1 Clinical China Immunotech Co Ltd Lymphoma, Non-Hodgkin Details
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) Phase 1 Clinical Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
SM-03 SM-03; SM-06 Phase 3 Clinical Lonn Ryonn Pharma Ltd, Sinomab Bioscience Ltd Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin Details
CD19/CD22 bispecific CAR-T (Zhejiang University) Details

This web search service is supported by Google Inc.

totop